Thomas Osborne

Building and investing in Bio x AI: NewCo, @Verily, @McKinsey, @FlatironHealth, @Microsoft. Views are my own.

[Thomas Osborne @ThomasOsborne]

@AdamDraper Right here

[Thomas Osborne @ThomasOsborne]

@ClaudeDevs Need help - I moved my CMA multi-agent setup from API to API via AWS. I was on Tier 4, but the new workspace created with Tier 1. I'm waiting on support for a rate limit upgrade back to Tier 4, but meanwhile most my agents are stuck. Thanks!

[Thomas Osborne @ThomasOsborne]

@Ronalfa Very cool!

[Thomas Osborne @ThomasOsborne]

Asked for a chart, but blocked from installing matplotlib, agent tried: 1) writing its own pixel by pixel renderer - decent, 2) creating text-based bar charts - quite decent, 3) posting to a chart making website - scary, fortunately blocked

[Thomas Osborne @ThomasOsborne]

Claude code keeps suggesting we stop for the night. Is that some new way to curtail usage? No way!

[Thomas Osborne @ThomasOsborne]

Glimpse of the future. On an airplane. Claude Code on my laptop, controlling OpenClaw on a server, which is coding analyses of data on S3. Most surprising? The WiFi worked on United.

[Thomas Osborne @ThomasOsborne]

Local models were a disappointment. Even for basic tasks like deciding which group Slack messages merit a response, performance was poor — and they exposed real security risks. Still good for generating embeddings for memory.

[Thomas Osborne @ThomasOsborne]

Adding to the OpenClaw fervor, sharing quick reflections from a few days of standing up an internal AI scientist at our startup. Would love to hear from others building internal AI tools in bio — what's worked, what hasn't?

[Thomas Osborne @ThomasOsborne]

Prompt logic is surprisingly powerful (decision gates, task routing). You can “code” a surprising amount purely in English language, but I still want more programmatic control — e.g., message event hooks that let me pre- and post-process around the LLM call.

[Thomas Osborne @ThomasOsborne]

100%. The most important and valuable companies are always started in the downturn.

[Angelos Georgakis @angelosgeo]

Not sure which biotech investor needs to hear this, but... pessimists get to be right, optimists get to be rich. Fund those bold biotechs!!! 🔥

[Thomas Osborne @ThomasOsborne]

@andruyeung Would like to join

[Thomas Osborne @ThomasOsborne]

@davidycli Interesting take - thanks

[Thomas Osborne @ThomasOsborne]

Congrats Quibim team on the Series A! Excited for this milestone in the important work of building AI imaging biomarkers for personalized medicine and drug development, and proud to partner with you in the journey as an early investor.

[Quibim @QuibimBiomarker]

Thrilled to announce the successful closure of our $50M Series A. This funding propels our mission to redefine #medicalimaging and transform #healthcare. Huge thanks to our team and partners—together, we’re improving health outcomes worldwide.
https://t.co/rJmHPkoI2k

[Thomas Osborne @ThomasOsborne]

Winner of #JPM2025: Waymo

[Thomas Osborne @ThomasOsborne]

Looking forward to catching up with many friends and colleagues at #JPM2025 next week, and sharing more of what we’re building

[Thomas Osborne @ThomasOsborne]

@ankurnagpal Would love to see it